eltrombopag
Sign in to saveAlso known as ETB115, AMG531, SB-497115-GR, 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid
Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. It is a thrombopoietin receptor agonist. It is taken by mouth.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 461093150
- Drug.image
- eltrombopag.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 270
- Drug.tradename
- Promacta, Revolade, others
- Drug.MedlinePlus
- a609011
- Drug.DailyMedID
- Eltrombopag olamine
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- B02
- Drug.ATC_suffix
- BX05
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- ~52%
via Wikipedia infobox
Research
1,602 papers- Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.The New England journal of medicine · 2017
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.Lancet (London, England) · 2011
- Eltrombopag.Cancer treatment and research · 2011
- Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
- Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2021
via PubMed
Wikidata facts
- Mass
- 442.1641
Show 6 more facts
- chemical formula
- C₂₅H₂₂N₄O₄
- World Health Organisation international non-proprietary name
- eltrombopag
- isomeric SMILES
- CC1=CC=C(C=C1C)N2C(=O)/C(=N\NC3=CC=CC(=C3O)C4=CC=CC(=C4)C(=O)O)/C(=N2)C
- canonical SMILES
- CC1=CC=C(C=C1C)N2C(=O)C(=NNC3=CC=CC(=C3O)C4=CC=CC(=C4)C(=O)O)C(=N2)C
- defined daily dose
- 50
- Commons category
- Eltrombopag
via Wikidata · CC0
~6 min read
Article
9 sectionsContents
- Medical uses
- Development
- Clinical trials
- History
- Society and culture
- Legal status
- Research
- References
- External links
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 461093150 | image = eltrombopag.svg | image_class = skin-invert-image | width = 270 | alt = | caption =
| pronounce = | tradename = Promacta, Revolade, others | Drugs.com = | MedlinePlus = a609011 | DailyMedID = Eltrombopag olamine | pregnancy_AU = B3 | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = B02 | ATC_suffix = BX05 | ATC_supplemental =